Abstract: A composition for preventing or treating inflammatory disease and that is effective for inflammatory disease such as fulminant hepatitis and interstitial pneumonia. For such an objective, the present uses a culture supernatant obtained by culturing dental pulp stem cells as the active ingredient of the composition for preventing or treating inflammatory disease.

Abstract: Provided is a glass-resin laminate (1) having a laminating structure of at least three layers, the glass-resin laminate (1) including: a layer including a glass sheet (2); a layer including a resin layer (3); and an adhesive layer (4) for bonding the glass sheet (2) and the resin layer (3), in which a spectral transmittance of the adhesive layer (4) in at least a wavelength range of from 430 nm to 680 nm is 90% or more.

Abstract: A dopant host containing, in terms of mole %, 20 to 50% SiO2, 30 to 60% (exclusive of 30%) Al2O3, 10 to 40% B2O3, and 2 to 10% RO, wherein R represents alkaline earth metal, or being a laminate including a boron component volatilization layer containing, in terms of mole %, 30 to 60% SiO2, 10 to 30% Al2O3, 15 to 50% B2O3, and 2 to 10% RO, wherein R represents alkaline earth metal, and a heat resistant layer containing, in terms of mole %, 8 to 30% SiO2, 50 to 85% Al2O3, 5 to 20% B2O3, and 0.5 to 7% RO, wherein R represents alkaline earth metal. A process for producing a boron dopant for a semiconductor including the steps of slurrying a starting material powder containing a boron-containing crystalline glass powder, forming the slurry to prepare a green sheet, and sintering the green sheet.

Abstract: A sheet roll comprises two glass films and a coupling portion, wherein end portions of the glass films are coupled together via the coupling portion and the coupled glass films are rolled into a roll shape. The coupling portion is a sheet-like coupling member formed of a resin film and placed on the end portions of the two glass films in a rolling direction so as to span therebetween. The sheet-like coupling member includes wide joint portions joined respectively to the end portions of the two glass films, and a necked portion which is narrower than the wide joint portions and is formed at a middle portion of the sheet-like coupling member in the rolling direction.

Abstract: Provided is a laminate (1) obtained by integrally laminating glass sheets (4) on both surfaces of a resin sheet (2). The glass sheets (4) have a thickness of 300 ?m or less and end surfaces (4a) of the glass sheets (4) are chamfered.

Abstract: As a substance used as a contrast agent for a method of nuclear magnetic resonance analysis or a method of magnetic resonance imaging, a substance with high selectivity and high sensitivity was demanded. According to the present invention, when a polymer having, in a side chain thereof, a sequence of a 1H—13C—15N, 1H—15N—13C or 1H—13C—13C bond, that is, a structure labeled with stable isotopes of 13C and 15N, is used, the abundance of such a sequence in one molecule can be increased, and hence, high selectivity and higher sensitivity can be attained when used as a contrast agent.

Abstract: The present invention provides a method for testing mesothelioma comprising a step of determining a concentration of a human periostin protein in at least one type of sample of blood or pleural fluid of a subject. In the step of determining the concentration of human periostin protein, an antibody directed against human periostin protein may be used. The present invention further provides a kit for diagnosing mesothelioma, said kit comprising an antibody directed against human periostin protein. In the kit for diagnosing mesothelioma, the antibody directed against a human periostin protein may be an antibody that binds to a polypeptide consisting of an amino acid sequence set out in SE ID NO: 2.

Abstract: A dopant host containing, in terms of mole %, 20 to 50% SiO2, 30 to 60% (exclusive of 30%) Al2O3, 10 to 40% B2O3, and 2 to 10% RO, wherein R represents alkaline earth metal, or being a laminate including a boron component volatilization layer containing, in terms of mole %, 30 to 60% SiO2, 10 to 30% Al2O3, 15 to 50% B2O3, and 2 to 10% RO, wherein R represents alkaline earth metal, and a heat resistant layer containing, in terms of mole %, 8 to 30% SiO2, 50 to 85% Al2O3, 5 to 20% B2O3, and 0.5 to 7% RO, wherein R represents alkaline earth metal. A process for producing a boron dopant for a semiconductor including the steps of slurrying a starting material powder containing a boron-containing crystalline glass powder, forming the slurry to prepare a green sheet, and sintering the green sheet.

Abstract: Disclosed is a method for improving the filtering properties of a defatted soymilk peptide. Also disclosed is a defatted soymilk peptide having improved filtering properties. The filtering properties of a defatted soymilk peptide can be improved by adding a calcium salt to the defatted soymilk peptide in an amount of 0.6 wt % or more in terms of calcium content relative to the crude protein content. The resulting mixture is filtered once or more times to produce a defatted soymilk peptide having improved filtering properties. The defatted soymilk peptide is characterized by containing a calcium salt in an amount of 0.4 wt % or more in terms of calcium content relative to the crude protein content.

Abstract: Disclosed are a composition having an anti-inflammatory function and a therapeutic method using the composition, both of which are effective for inflammatory diseases such as inflammatory bowel disease. Specifically disclosed are: an anti-inflammatory functional agent for oral application, which comprises a soybean peptide, wherein the soybean peptide contains fractions each having a molecular weight of 500 or less and excluding any free amino acid in an amount of 40 wt % or more and has a free amino acid content of 7 wt % or less; and a therapeutic method using the anti-inflammatory functional agent.

Abstract: A sheet roll (1) is manufactured by placing a sheet-like coupling member (3) on end portions of a plurality of glass films (g) so as to span therebetween, coupling the end portions of the glass films (g) together, and rolling the coupled plurality of glass films (g). The sheet-like coupling member (3) used in the sheet roll (1) includes wide width portions (4) for forming wide joint portions joined to the glass films (g) at each of both end portions thereof in a rolling direction, and a necked portion (5), which is narrower than the wide width portions (4) and is formed at a middle portion thereof in the rolling direction.

Abstract: To manufacture a roll body (glass roll) of the glass film, which is subjected to a tension application, and is free from looseness, without adversely affecting the formation of the glass film and causing a problem such as cracks, provided is a method of manufacturing a glass roll (1), including: forming a glass film (2) by a downdraw method; and winding the formed glass film (2) into a roll while superposing the glass film (2) on a protective sheet (3), in which the glass film (2) and the protective sheet (3) are wound while higher tension in a winding direction is applied to the protective sheet (3) than to the glass film.

Abstract: A roll-to-roll apparatus reliably reduces breakage of a glass film even in a case of sequentially performing predetermined processing on the glass film. Provided is a glass roll (1) formed by winding a glass film (2) into a roll, in which a resin film (4) is attached onto the glass film (2), and at least a part of the resin film (4) is arranged on a front side of an unwinding direction relative to a leading end portion in the unwinding direction of the glass film (2).

Abstract: A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan.

Abstract: Disclosed is a method for improving the filtering properties of a defatted soymilk peptide. Also disclosed is a defatted soymilk peptide having improved filtering properties. The filtering properties of a defatted soymilk peptide can be improved by adding a calcium salt to the defatted soymilk peptide in an amount of 0.6 wt % or more in terms of calcium content relative to the crude protein content. The resulting mixture is filtered once or more times to produce a defatted soymilk peptide having improved filtering properties. The defatted soymilk peptide is characterized by containing a calcium salt in an amount of 0.4 wt % or more in terms of calcium content relative to the crude protein content.

Abstract: A dopant host containing, in terms of mole %, 20 to 50% SiO2, 30 to 60% (exclusive of 30%) Al2O3, 10 to 40% B2O3, and 2 to 10% RO, wherein R represents an alkaline earth metal, or including a laminate including a boron component volatilization layer containing, in terms of mole %, 30 to 60% SiO2, 10 to 30% Al2O3, 15 to 50% B2O3, 2 to 10% RO, wherein R represents an alkaline earth metal, and a heat resistant layer containing, in terms of mole %, 8 to 30% SiO2, 50 to 85% Al2O3, 5 to 20% B2O3, and 0.5 to 7% RO, wherein R represents an alkaline earth metal. A process for producing a boron dopant for a semiconductor includes the steps of slurrying a starting material powder containing a boron-containing crystalline glass powder, forming the slurry to prepare a green sheet, and sintering the green sheet.

Abstract: A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan.

Abstract: An information storage medium includes: a plurality of unit audio information to be reproduced independently of each other; aggregate audio information each including one or more of the unit audio information; unit attribute information indicating attributes of the unit audio information included in the aggregate audio information; and aggregate attribute information including the unit attribute information corresponding to the aggregate audio information recorded on the storage medium. By referring to the aggregate attribute information, the attributes of all the unit audio information may be readily and quickly obtained.

Abstract: A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan; and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drug reaction, thereby reducing the adverse drug reaction cased by the administration of irinotecan.

Abstract: An information record medium (1) is provided with: an audio information recording area on which a plurality of audio information (210) which are different in recording method are recorded; and a control information recording area on which control information (211) required to reproduce the plurality of audio information recorded on the audio information recording area is recorded. The control information recorded on the control information recording area includes a plurality of first division information for identifying first division units (260) respectively so as to divide each of the plurality of audio information recorded on the audio information recording area by the first division units respectively. The first division information, which indicates that the audio information divided by the first division units belongs to a same first division unit, is provided for each of the plurality of audio information same in content and different in recording method.